2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methoxypropan-2-yl)acetamide;2-[(2-chlorophenyl)methyl]-4,4-dimethyl-1,2-oxazolidin-3-one;N-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-1,2,4-triazol-1-yl]phenyl]methanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methoxypropan-2-yl)acetamide;2-[(2-chlorophenyl)methyl]-4,4-dimethyl-1,2-oxazolidin-3-one;N-[2,4-dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-1,2,4-triazol-1-yl]phenyl]methanesulfonamide
• 化学式: C38H46Cl4F2N6O7S
• 分子量: 910.7
• InChiKey: JGEIPGTYZUJNLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.22
• 重原子数：
  58
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  150
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• FORMULATIONS OF CLOMAZONE
  申请人：FMC Corporation

  公开号：EP2877026A1

  公开（公告）日：2015-06-03
• [EN] FORMULATIONS OF CLOMAZONE<br/>[FR] FORMULATIONS DE CLOMAZONE
  申请人：FMC CORP

  公开号：WO2014018188A1

  公开（公告）日：2014-01-30

  New formulations of clomazone are provided, as well as new methods for making formulations of clomazone. The new formulations provide improved efficacy, decreased volatility, and/or increased loading of clomazone over the clomazone formulations in the prior art.